Evidence map›Paper›PMID 38435073›Full record

ArticleKidney medicine2024

Mycophenolate Mofetil Versus Prednisone for Induction Therapy in Steroid-Sensitive Idiopathic Nephrotic Syndrome in Children: An Observational Study.

Alexandra Mazo, Stella Kilduff, Tanya Pereira, Sonia Solomon, Robin Matloff, Anna Zolotnitskaya, Dmitry Samsonov

Open access · goldAbstract read
In one paragraph

Article in Kidney medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Alexandra MazoPediatric Nephrology Division, Maria Fareri Children's Hospital, Westchester Medical Center, Boston Children's Health Physicians, New York Medical College, Valhalla, New York.
Stella KilduffPediatric Nephrology Division, Ann and Roberst H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Tanya PereiraPediatric Nephrology Division, Maria Fareri Children's Hospital, Westchester Medical Center, Boston Children's Health Physicians, New York Medical College, Valhalla, New York.
Sonia SolomonPediatric Nephrology Division, Maria Fareri Children's Hospital, Westchester Medical Center, Boston Children's Health Physicians, New York Medical College, Valhalla, New York.
Robin MatloffPediatric Nephrology Division, Connecticut Children's, University of Connecticut School of Medicine, Hartford, Connecticut.
Anna ZolotnitskayaPediatric Nephrology Division, The Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York.
Dmitry SamsonovPediatric Nephrology Division, Maria Fareri Children's Hospital, Westchester Medical Center, Boston Children's Health Physicians, New York Medical College, Valhalla, New York.
Westchester Medical Center · USAlbert Einstein College of Medicine · USNorthwestern University · USUniversity of Connecticut · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale & Objective: High-dose steroids are recommended for the induction of idiopathic nephrotic syndrome. The aim of this study was to compare standard induction therapy with Mycophenolate Mofetil (MMF). We hypothesized that MMF could be noninferior to steroids in maintaining steroid-induced remission. The second aim was to reduce steroid-induced side effects. Study Design: This was an observational study. Setting & Population: Patients 2-11 years with first episode of nephrotic syndrome who entered remission within 2 weeks of standard steroid treatment were eligible for enrollment. Patients in the experimental group completed 12-week induction with MMF, whereas the control group continued a standard 12-week steroid protocol. Exposures: MMF and prednisolone were used in the study. Outcomes: The primary study outcomes were relapse rate and relapse-free interval during a 52-week follow-up. Analytical Approach: Descriptive statistics were used for analysis. Results: Ten of 41 eligible patients consented to participate in the MMF group and 8 completed the study. The control group included 31 patients, with 23 patients who completed 52 weeks follow-up. During the induction phase, 3 out of 10 patients (30%) in the MMF group and 1 out of 31 (3%) in the control group ( Limitations: The limitations of the study were low patient numbers receiving MMF and single-center design. Conclusions: Our small cohort of patients treated with MMF reported a higher relapse rate during the induction phase. However, by 12 months of follow-up the relapse rate and relapse-free intervals were similar between both groups. All patients tolerated MMF without significant side effects, and those who relapsed remained steroid-sensitive.

Indexed as

inductionMinimal change diseasemycophenolate mofetilprednisonerelapse

Identifiers

PMID38435073
PMCPMC10904994
OpenAlexW4389523160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.